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hospitalisations and laboratory tests. This trial also reported rel-
ative safety and efﬁcacy. Australian cost data were applied to the
resource utilisation from the trial to estimate the overall treat-
ment costs associated with each therapy. Study drug and con-
comitant medication prices were sourced from the Schedule of
Pharmaceutical Beneﬁts and E-MIMS, while national casemix
costs were applied to hospitalisations. Rather than episodic
costing, a mixture of ﬁxed and marginal costs were used. Labo-
ratory test prices were from the Medicare Beneﬁts Schedule.
RESULTS: The overall cost of therapy for olanzapine patients
was AUS$9340 (US$6457), compared with A$9589 (US$6629)
for lithium patients. Although the acquisition cost of olanzapine
is greater than for lithium, the fewer (82 vs. 88) and shorter 
hospitalisations (15 vs. 19.7 days) associated with olanzapine
relative to lithium therapy lead to this overall cost saving of
AUS$249 (US$172). Olanzapine patients do not require labora-
tory tests to monitor serum lithium levels, which also contributes
to the cost saving. In terms of efﬁcacy, 8.8% (p = 0.055) fewer
olanzapine patients relapsed compared with lithium patients.
Additionally, 13.7% (p < 0.001) fewer olanzapine patients suf-
fered manic relapse. Time to relapse analysis conﬁrmed that ben-
eﬁts from olanzapine are maintained over a longer period than
those of lithium. Hence, the probability of relapse diverges over
time. When costs were varied in sensitivity analyses, olanzapine
continued to be cost-effective. CONCLUSIONS: Olanzapine dis-
plays greater efﬁcacy and is cost-saving compared to lithium.
Hence, olanzapine represents a dominant therapeutic option.
Sensitivity analysis indicated that even in extreme circumstances,
olanzapine remains cost-effective.
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OBJECTIVE: To examine mental health medical services uti-
lization and costs for patients in the depressive phase of bipolar.
METHODS: This retrospective study included a cohort of 1419
patients who had 3 consecutive years of data (majority between
1999 and 2001), received a diagnosis of bipolar depression (ICD
codes), and utilized one of three types of medical services; room
and board, medical/surgical, and ancillary services associated
with a mental disorder diagnosis. Medical service utilization and
costs were observed for a 1-year period post diagnosis index.
RESULTS: Twenty-one percent of patients incurred hospitaliza-
tion charges, averaged two admissions per year and accounted
for 50% of medical service costs. Average annual medical service
costs for patients who continue their initial treatment are $1950.
These cost more than triple ($6570) for patients who incur three
or more switches in a year. Additionally, the largest increase in
medical service costs is from the initial treatment ($1950) to the
ﬁrst switch ($3364). Bipolar depressed patients who received no
psychotropic medication incurred $3903 of medical service
costs. CONCLUSION: Patients with more “stabilized” treat-
ment had lower medical service costs than those patients who
experienced switches in pharmacologic treatment. Additionally,
non-medicated bipolar depressed patients incur high annual
costs to the managed care organization.
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OBJECTIVE: Prescribing patterns in bipolar disorder are
complex and varied. The objective of this analysis was to iden-
tify how various patterns of treatment relate to direct costs.
METHODS: The PharMetrics Integrated Outcomes Database 
of adjudicated medical and pharmaceutical claims for over 3
million patients from 11 U.S. health plans was utilized. 3,648
bipolar patients were identiﬁed based on the following criteria:
two claims with ICD-9-CM diagnosis for bipolar disorder
(296.0, 296.1, 296.4–296.8) that were not accompanied by a
unipolar depression claim on the same day, age between 10 and
64, and 1 year of continuous eligibility prior to and following
the initial bipolar diagnosis. Thirteen months of data were ana-
lyzed (1 month pre diagnosis, 12 months post diagnosis).
RESULTS: Eighty-two percent of patients (2992) were treated
with medication. For drug treated patients, on average, the total
cost over the 13-month period is $12,416 per patient. Of this
amount, 65% of the costs ($8018) are bipolar-related; with a 
5 :1 ratio of medical services related costs ($6,691) to medica-
tion costs ($1327). Patients initiating on poly-pharmacy incur
higher total bipolar costs ($10,137) than their cohorts who ini-
tiated on mono therapy ($6,683). As expected, as the number of
drugs used increases, total bipolar costs steadily rise with the
average being $3,883 for one drug, $11,419 for four drugs and
$19,040 for 9 drugs. Additionally, as the number of treatment
regimes per patient increases, so do costs. Total bipolar costs for
patients having only one treatment regime average $3,528,
whereas patients experiencing 3 switches (four regimes) average
$12,553. CONCLUSION: Many factors are related to the cost
of treating bipolar patients. Further investigation needs to be
conducted in order to understand which of these factors might
be cost containment opportunities.
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OBJECTIVE: To assess cost consequences associated with dif-
ferent initial therapies and comorbidity factors for patients with
bipolar disorders in a managed care Medicaid population.
METHODS: Using a multi-state claims database from January
1998 to December 2002, 3676 newly treated bipolar patients
were selected if they had not been treated during the preceding
3-months and had a minimum 3-month follow-up period and at
least two bipolar-related diagnoses and prescriptions. The cost
consequence measured by total charge was further divided into
bipolar-related and or not. Using Poisson regression analysis,
costs were regressed on patient’s age, gender, initial therapy,
major psychiatric disorders, and general clinical comorbidities.
RESULTS: The cohort patients had 87.9% bipolar I, 66.6%
female, average age of 27.2 (SD 13.8). Initial therapy involved
atypical antipsychotics monotherapy (12.4%), lithium/anticon-
vulsants (22.6%), combination of atypical and lithium or anti-
convulsant (31.1%), other combination of typical antipsychotics
and antidepressants (33.9%). Bipolar-related cost was relatively
stable overtime with monthly average of $384 (SD 845), and sig-
niﬁcantly associated with bipolar I (Odds Ratio = 1.30; 95% CI
1.056–1.63), major depression (OR 1.74; 1.51–2.02), substance
abuse (OR 1.67; 1.44–1.94), anxiety disorder (OR 1.18;
1.04–1.34), impulse control disorder (OR 1.40; 1.17–1.67), per-
sonality disorder (OR 1.46; 1.20–1.76), eating disorder (OR
1.93; 1.28–2.76). The total health care cost (bipolar and non-
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bipolar) increased overtime with monthly average of $1432 (SD
2551). In addition, total cost was also signiﬁcantly associated
with general comorbidities like diabetes mellitus (OR = 1.34;
95% CI 1.14–1.56), cancer (OR 1.73; 1.07–2.63), hypertension
(OR 1.63; 1.41–1.88), COPD (OR 1.41; 1.35–1.96), cerebra-
vascular disease (OR 1.94; 1.59–2.35), and ischemic heart
disease (OR 1.89; 1.53–2.34). CONCLUSION: Bipolar related
cost is associated with bipolar I disorder, psychological disor-
ders, and use of antipsychotics therapy. In addition, the total
health care cost is signiﬁcantly associated with general clinical 
comorbidities.
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OBJECTIVE: The objective is to quantify the epidemiological
patterns and medical cost of patients treated for both Attention-
Deﬁcit/Hyperactivity Disorder (ADHD) and epilepsy
(ADHD/epilepsy). METHODS: We analyzed a de-identiﬁed
administrative claims database (approximately 600,000 lives
under the age of 65, 1998 to 2001) for commercially insured
populations to assess the treated prevalence rate as well as the
incremental cost of epilepsy among ADHD patients 18 years old
or younger. These measures were computed for the ADHD
patients treated for epilepsy (n = 64) compared to a control
group of epilepsy patients without ADHD (“non-ADHD”) of the
same age (n = 107) in a random sample. We investigated the
validity of the results using a similar, supplemental database.
RESULTS: The treated prevalence rate of epilepsy is 1.5%
among ADHD patients versus 0.5% among non-ADHD
patients. The odds ratio of epilepsy treatment given an ADHD
diagnosis is 3.2. ADHD/epilepsy patients are treated for mental
disorders 3.6 times more than non-ADHD patients (41.0% vs.
11.4% of patients, respectively, p < 0.0001). The average annual
costs are $4365 for ADHD/epilepsy patients and $3568 for con-
trols; the difference is not statistically signiﬁcant. These costs
were primarily for non-mental health diagnoses. However, the
cost of mental health treatment of ADHD/epilepsy patients was
15 times higher than that for non-ADHD patients (p = 0.01).
Patterns of results were similar in the second database. However,
because this study relied on insurance claims data, the ﬁndings
apply to clinical practice as opposed to tightly diagnosed
research samples. CONCLUSIONS: Epilepsy is more common
among ADHD patients than the general population.
ADHD/epilepsy patients use more health care services and cost
more than epilepsy-only patients.
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OBJECTIVE: Although it is widely accepted that stimulants are
used as the treatment of choice, many decision makers do not
have appropriate information regarding an optimal ﬁrst-line
agent in treating this patient population. We evaluated the 
cost-effectiveness in choosing methylphenidate (RitalinTM) or
amphetamine/ dextroamphetamine (AMP/DEX) mixed salts
(AdderallTM) as a ﬁrst-line agent in the treatment of ADHD.
METHODS: Decision-tree analysis was performed using
weighted utility and weighted cost outcomes after basing deci-
sions on three treatment arms: Initiation with methylphenidate,
initiation with AMP/DEX, or no treatment. Data inputs such as
efﬁcacy rates, side effects, compliance rates, and school admin-
istration rates were extracted from a literature review. A societal
perspective was used to estimate outcomes in terms of incre-
mental cost and incremental utilities over the time horizon of one
year. RESULTS: In the base case analysis, AMP/DEX dominates
both methylphenidate and using no treatment. The ICE ratio for
AMP/DEX versus no treatment is $21,931/ QALY. Total costs
for the AMP/DEX arm were $2999 with a QALY score of 0.889.
The methylphenidate arm reports total costs of $3043 and a
QALY score of 0.839, and those who received no treatment
achieved total costs of $993 and a QALY score of 0.798. Sensi-
tivity analysis shows that major drivers of this conclusion
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